Clinical Trial Update: GC012F Injection in Refractory Idiopathic Inflammatory Myopathy [EARLY_Phase 1]

View source ↗

Summary

An early-phase clinical trial update indicates GC012F injection is being evaluated for refractory idiopathic inflammatory myopathy and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathy

Drugs mentioned

• GC012F

Snippet

Sponsor: Daishi Tian | Conditions: Idiopathic Inflammatory Myopathy (IIM) | EARLY_Phase 1 | Status: RECRUITING